CANNAINVESTOR Magazine U.S. Publicly Traded April 2018 | Page 72

NanoSphere researches, develops and commercializes a diverse line of product formulations based on the NanoSphere Delivery System™ to meet the needs of healthcare providers, consumers and suppliers. The NanoSphere Delivery System™ is the first to apply nanotechnology to improve the bioavailability and efficacy of essential ingredients and medications. This disruptive technology introduces a significant advancement in these industries. NHS is the only nanotechnology company who plans to offer vertically integrated, commercial lines. Left: Evolve Formulas’ game-changing transdermal product NanoSerum™, enables cannabis to be rapidly absorbed into systemic circulation for direct-focus relief from pain, inflammation and anxiety. Strategic Direction Technology & Innovation NanoSphere’s initial product deployment is NanoSphere has developed a revolutionary, for the cannabinoid market, targeting both multiple patent-pending method for the the medical marijuana market and, where non-invasive delivery of bioactive compounds, legalized, the recreational usage market. such as cannabinoids, nutraceuticals, NanoSphere has already partnered with a pharmaceuticals and over-the-counter medications, into licensee in Colorado, and in late spring the body with greater efficiency than many traditional delivery systems. The 2017 launched its first award-winning NanoSphere Delivery System™ encapsulates these compounds in protective cannabinoid product line, branded Evolve nano-sized spheres for transport directly into the bloodstream and cells. Our NanoSerum, in the Colorado market. ongoing research and successful pharmacokinetic blood studies of our NanoSphere will further license its technology have confirmed the greater bioavailability, bioactivity and efficacy of intellectual property and proprietary our delivery system. manufacturing method to selected cannabis cultivators, extractors and distributors on a state-by-state basis and abroad, and is currently in discussions with operators in several states to replicate the business model in Colorado. Other planned future deployments include nutraceuticals, nonsteroidal anti-inflammatory drugs and animal health applications. Intellectual Property Overview Our patent-pending portfolio includes: U.S. patent-pending 61/890,773: Nutraceutical Delivery Utilizing Nano Particle Compositions, 62/091,994: Nanoparticle Encapsulation To Treat And Prevent Global Inflammation And Pain, 62/130,775: Lipid Nanoparticle Compositions and Methods as Carriers of Cannabinoids. CSE: NSHS